FURMAN et al. V. BELLEAU et al. - Page 8









                                No-rs-:                                                                                 
                                                  N                                                                     
                                            O'k-r                                                                       
                                               N                                                                        
                                                  NH2                                                                   




                           which is substantially free of the corresponding                                             
                           (+)-enantiomer or contains more of said (-)-enantiomer than the                              
                           corresponding (+)-enantiomer, or a pharmaceutically acceptable                               
                           salt, ester or salt of an ester thereof                                                      


                    Count 3 reads as follows:                                                                           
                           A method of treating hepatitis B virus infection and/or inhibiting                           
                           hepatitis B virus replication in a patient in need thereof, including                        
                           humans and other mammals, comprising administering to said                                   
                           patient an effective amount of (-)-cis-4-amino- 1 -(2                                        
                           hydroxymethyl-1,3-oxathiolan-5-yl)-(I H)-pyrimidin-2-one of the                              
                           formula:                                                                                     









                                                         8                                                              






Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next 

Last modified: November 3, 2007